2018 Oncology Annual Meeting Phase III Trial Data You Can’t Miss

The 2018 American Society of Clinical Oncology (ASCO) Annual Meeting begins tomorrow at the McCormick Place Convention Center in Chicago, Illinois. More than 39,000 participants from around the world are expected to attend this meeting to share the latest advances in cutting edge oncology research and patient care over the next five days. The theme […]

Read More

High Major Pathologic Response With Neoadjuvant Nivolumab in Resectable NSCLC

Immunotherapies targeting PD-1 and PD-L1 have become standards-of-care across all lines of therapy for patients with metastatic non-small cell lung cancer (NSCLC) who do not have targetable driver mutations. Furthermore, the PD-L1 inhibitor durvalumab was recently approved as consolidation therapy after chemoradiation in locally advanced NSCLC.  Based on the improved outcomes seen with these agents […]

Read More

Immunoscore Reliable to Estimate Risk of Recurrence in Early CRC

Currently, the risk of recurrence after surgery for patients with colorectal cancer (CRC) is estimated based on histopathological criteria of tumor invasion according to the American Joint Committee on Cancer (AJCC) and TNM classification system and on features of tumor cell differentiation. In recent years, the role of the immune system in cancer patient outcomes […]

Read More

EMA-recommendations-primeoncology_2017

EMA Positive Opinions to Expand Oncology Treatment Options in Europe

In March and April 2018, the European Medicines Agency (EMA) issued several positive opinions that recommended approval or expanded indications for oncology/hematology agents. All but one of these agents has been previously approved by the US Food and Drug Administration (FDA) for similar indications. Osimertinib for First-Line EGFR-Mutant NSCLC. The EMA granted a positive opinion […]

Read More

Total Neoadjuvant Therapy Improves R0 Resection Rate in Borderline Resectable Pancreatic Adenocarcinoma

For patients with localized pancreatic adenocarcinoma with some degree of vascular involvement (as defined by National Comprehensive Cancer Network [NCCN]), termed borderline resectable, management has been heterogeneous and includes neoadjuvant chemoradiation, surgery, and most recently, neoadjuvant therapy. Retrospective data indicate that neoadjuvant chemotherapy can improve rates of R0 resection in patients with borderline resectable disease. […]

Read More

CLL,venetoclax/Rituximab

Venetoclax Induces Durable Responses in R/R CLL With 17p Deletion

In patients with chronic lymphocytic leukemia (CLL), deletion of chromosome 17p [del(17p)] or mutation in TP53 is associated with poor prognosis and resistance to many standard therapies. The recent emergence of targeted therapies has expanded available treatment options for these patients. The B-cell lymphoma 2 inhibitor venetoclax was approved for the treatment of CLL with […]

Read More

palbociclib-fulvestrant-breast-cancer-primelines

Continued Benefit of 1st-Line Ribociclib and Letrozole in HR+ BC

For first-line treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in combination with aromatase inhibitors (AIs) has become the standard of care. There are currently three CDK 4/6 inhibitors approved for first-line use in combination with hormonal therapy: palbociclib, ribociclib, and abemaciclib. […]

Read More

Estrogen HRT Post-Oophorectomy Doesn’t Increase BRCA1 Carrier BC Risk

Women harboring BRCA1 germline mutations have an estimated 44% lifetime risk for developing ovarian cancer. Bilateral salpingo-oophorectomy is the most effective prophylactic measure to reduce the risk of ovarian cancer in these women. However, this surgical intervention is associated with early menopause and long-term consequences of abrupt ovarian hormonal withdrawal.  Hormone replacement therapy (HRT) is […]

Read More

Five FDA Approvals for Oncology Agents in April

Adjuvant Dabrafenib/Trametinib for BRAF-Positive Melanoma. The combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib (Tafinlar® and Mekinist®, Novartis Pharmaceuticals) was approved for use as adjuvant therapy in patients with BRAF V600E or V600K-positive stage III melanoma following complete resection. This decision was based on results from the phase III COMBI-AD study, which […]

Read More